Effect of tolazoline on persistent hypoxemia in severe hyaline membrane disease.
10.3349/ymj.1990.31.2.156
- Author:
Kook In PARK
1
;
Ran NAMGUNG
;
Chul LEE
;
Dong Gwan HAN
Author Information
1. Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Tolazoline;
hyaline membrane disease;
persistent hypoxemia
- MeSH:
Anoxemia/*drug therapy;
Human;
Hyaline Membrane Disease/*complications;
Infant;
Infant, Newborn;
Infusions, Intravenous;
Support, Non-U.S. Gov't;
Tolazoline/administration & dosage/*therapeutic use
- From:Yonsei Medical Journal
1990;31(2):156-162
- CountryRepublic of Korea
- Language:English
-
Abstract:
Ten critically-ill preterm infants with severe hyaline membrane disease received tolazoline because of persistent hypoxemia refractory to the administration of 100% oxygen and mechanical ventilation. Seven infants (70%) responded immediately with an increase in PaO2 greater than or equal to 20 mmHg in the umbilical arterial gas within 60 minutes after bolus infusion (1 to 2 mg/kg) of tolazoline. Twenty-four hours later after the tolazoline infusion, the FiO2 had been decreased from 1.0 to a mean of 0.82 +/- 0.16, and the MAP from 16.5 +/- 1.8 to 15.6 +/- 4.5 cm H2O. Four of 7 infants (57%) who had an immediate response survived, whereas none survived out of 3 infants who failed to respond initially. Three infants experienced relatively severe complications possibly related to tolazoline. There appears to be a place for the use of tolazoline in a severely hypoxemic infant with hyaline membrane disease who is being ventilated, and in whom arterial oxygenation cannot be improved by a further increase in the inspired oxygen concentration or by an alteration of ventilator settings.
